The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors.
 
Haifeng Qin
No Relationships to Disclose
 
Yongsheng Wang
No Relationships to Disclose
 
Yuyao Yi
No Relationships to Disclose
 
Fang Gao
No Relationships to Disclose
 
Dongling Zou
No Relationships to Disclose
 
Yongsheng Li
No Relationships to Disclose
 
Xiubao Ren
No Relationships to Disclose
 
Dongmei Ji
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Shasha Wang
No Relationships to Disclose
 
Zhen Zeng
No Relationships to Disclose
 
Jing Yu
No Relationships to Disclose
 
Liqing Ma
No Relationships to Disclose
 
Yishan Liu
No Relationships to Disclose
 
Lili Lu
No Relationships to Disclose
 
Derun Shen
No Relationships to Disclose
 
Xue Zhai
No Relationships to Disclose
 
Pin Wang
Stock and Other Ownership Interests - Immune Design Corp
Consulting or Advisory Role - TCRCure Biopharma Inc.
Patents, Royalties, Other Intellectual Property - A technology for engineering dendritic cells for targeted vaccination. A series of patents was awarded to California Institute of Technology and University of Southern California. Immune Design Corp. has licensed these patents, in which certain royalties
 
Yarong Liu
No Relationships to Disclose